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Abstract
Cystic fibrosis is an autosomal recessive genetic disease, produced by a mutation in the CFTR gene that impairs its
function as a chloride channel. In this work, we have examined the effects of interleukin-1L (IL-1L) on the expression of
CFTR in human colonic T84 cells. Treatment of T84 cells with IL-1L (0.25 ng/ml) for 4 h resulted in an increased CFTR
expression (mRNA and protein). However, higher doses of IL-1L (1 ng/ml and over) produced inhibition of CFTR mRNA
and protein expression. The protein kinase C (PKC) inhibitors H7 (50 WM) and GF109203X (1 WM) inhibited the stimulatory
effect of IL-1L. Similar effects were seen in the presence of the protein tyrosine kinase (PTK) inhibitors genistein (60 WM) and
herbymicin A (2 WM). These results suggest that some PKC isoform(s) and at least a PTK might be involved in the CFTR up-
regulation induced by IL-1L. The repression of CFTR up-regulation by cycloheximide (35.5 WM) suggests the participation
of a de novo synthesized protein. Results obtained by using the RNA polymerase II inhibitor DRB (78 WM), suggest that the
increased mRNA levels seen after IL-1L treatment are not due to an increased stability of the message. We conclude that the
CFTR mRNA and protein levels are modulated by IL-1L, this cytokine being the first extracellular protein known to up-
regulate CFTR gene expression. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Cystic ¢brosis is the most common life-threatening
autosomal recessive genetic disorder in Caucasian
populations. The disease a¡ects primarily epithelial
tissues of airway, intestine, pancreatic duct, genital
tract, and sweat glands [1]. A failure in the cystic
¢brosis transmembrane conductance regulator
(CFTR) gene product is responsible for the disease
[2]. The product of the gene is a chloride channel,
which is regulated by protein kinase A phosphoryla-
tion [3,4] and belongs to a family of ATPase-depen-
dent transporters [5]. More than 900 mutations have
been reported [6]. The most important for the CFTR
function is a deletion of a phenylalanine at position
508 (vF508) [7].
Airway obstruction and chronic endobronchial in-
fection have been known for a long time to be im-
portant factors in the pathogenesis of lung disease in
cystic ¢brosis (CF). However, it was only recently
recognized that the in£ammatory process may play
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an important role in lung damage [8]. In the respira-
tory airway, lymphoid cells are found adjacent to the
secretory epithelium and produce cytokines in re-
sponse to acute and chronic in£ammation or infec-
tion [9]. Among the di¡erent cytokines produced by
these cells, interleukin-1L (IL-1L) is particularly in-
teresting since it has been found elevated in sputum
samples from CF patients [10]. IL-1L can stimulate a
wide range of cell types besides those with roles in
immunity and in£ammation [11]; however, its e¡ects
on CFTR mRNA or protein levels are unknown.
Studies done by other researchers using HT29 and
T84 colon epithelial-derived tumor cells lines, known
to express the CFTR gene, have demonstrated that
IFN-Q [12] and TNF-K [13] down-regulate CFTR
mRNA transcript levels, in a dose- and time-depen-
dent manner. We have also used T84 cells as a
model system to study the e¡ects of IL-1L on
CFTR gene expression, since in these cells the
CFTR gene is highly expressed and the IL-1 receptor
is also present [14]. Using this model system, we have
obtained evidence that IL-1L up-regulates the steady-
state levels of the CFTR mRNA and protein, being
the IL-1L ¢rst extracellular up-regulator described
for CFTR.
2. Materials and methods
2.1. Cell culture and treatments
T84 human colon carcinoma cells (ATCC cell line
CCL248, Rockville, MD) were grown in DMEM-
F12 1:1 mixture supplemented with 10 U/ml penicil-
lin, 10 mg/ml streptomycin, 5% fetal bovine serum
(Life Technology, Gaithersburg, MD). Sub-con£uent
cells (70^75%) were incubated in serum-free medium
(10 ml in 100-mm Petri dishes) for 48 h and then IL-
1L was added to the medium at di¡erent concentra-
tions, as indicated in the legend to the ¢gures. For
inhibition experiments, the cells were preincubated
with di¡erent inhibitors for 30 min before adding
IL-1L. To inhibit protein kinase C (PKC), we used
H7 (1-(5-isoquinolinesulfonyl)-2-methylpiperazine
HCl) (Sigma, St. Louis, MO), at a ¢nal concentra-
tion of 50 WM [15] and the highly selective PKC
inhibitor GF109203X (bisindolyl-maleimide I) (Sig-
ma, St. Louis, MO), at a ¢nal concentration of
1 WM [16]. To inhibit protein tyrosine kinases, we
used genistein (4,5,7-trihydroxyso£avone) (Sigma,
St. Louis, MO), at a ¢nal concentration of 60 WM
[17] and herbymicin A (Sigma, St. Louis, MO), at a
¢nal concentration of 2 WM [18]. Cycloheximide was
used as inhibitor of protein synthesis (Sigma, St.
Louis, MO), at a ¢nal concentration 35.5 WM [19].
DRB (5,6-dichloro-1-L-D-ribofuranosylbenzimida-
zole) (Sigma, St. Louis, MO), which inhibits RNA
polymerase II causing premature termination of tran-
scription, was used at a ¢nal concentration of 78 WM
[20]. TPA (12-o-tetradecanoylphorbol-13-acetate),
(Sigma, St. Louis, MO) was used at a ¢nal concen-
tration of 100 ng/ml (0.16 WM) as a control for
down-modulation of the CFTR gene [21].
2.2. Preparation of total RNA
A guanidine-isothiocyanate denaturation proce-
dure with subsequent phenol-chloroform extraction
of the proteins was used as reported before [22].
The mRNA was precipitated from 50% isopropanol
and the ratios at A260/A230 (greater than 2.0) and
A260/A280 (from 1.7 to 2.0) were determined to verify
RNA purity.
2.3. Northern blots
For Northern blot analysis, equal amounts of total
RNA (30 Wg) were electrophoresed on 1% agarose
gels containing 2.2 M formaldehyde and transferred
to Nytran membranes [22]. After transference, RNA
was stained using a solution of 0.04% methylene blue
in 0.5 M sodium acetate (pH 5.2), scanned and quan-
ti¢ed (NIH Image program) to control sample load-
ing [22]. The membranes were hybridized at 65‡C
with a 3.3-kb CFTR cDNA probe (ATCC 61136),
labeled with 32P ([K-32P]dCTP, 3000 Ci/mmol, New
England Nuclear, Boston, MA) by random priming
(Prime a gene labeling system, Promega, Madison,
WI), washed at 65‡C and exposed for various times
at 370‡C using an intensifying screen as indicated
previously [22].
2.4. Immunoblot analysis of CFTR expression
Subcon£uent monolayers of T84 cells (2 days in
serum free DMEM-F12), were incubated for 4 h in
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the presence/absence of IL-1L or TPA. The mono-
layers were washed with ice-cold PBS and lysated in
Ripa bu¡er (25 mM Tris, 150 mM NaCl, 0.5% DOC,
1% NP40, 2 mM EDTA, pH 8). Nuclei and unbrok-
en cells were removed by centrifugation (15 000Ug
for 15 min at 4‡C). Soluble proteins in the super-
natant were denatured with Laemmli sample bu¡er,
fractionated on 7% PAGE gels and transferred to a
nitrocellulose membrane. Transferred proteins were
probed with the monoclonal anti-CFTR antibody
M3A7 [23], generously provided by Dr. J.R. Rior-
dan. The primary antibody was visualized by using
horseradish peroxidase-conjugated anti-mouse im-
munoglobulin and the enhanced chemiluminescence
(ECL) Western blot kit (Amersham, Little Chalfont,
Buckinghamshire, UK).
2.5. Quanti¢cation and statistical analysis
Northern an Western blots were scanned in an
HP4C scanner and quanti¢ed by using the NIH Im-
age program PC compatible (http://www.scioncorp.
com). Sample loading in Northern blots was quanti-
¢ed by using methylene blue staining. A lineal re-
sponse to methylene blue staining was obtained up
to 40 Wg of total RNA, therefore, a maximum of 30
Wg was used in each assay. Statistical analysis was
done by ANOVA and Tukey HSD test.
3. Results and discussion
We ¢rst studied the possible e¡ects of IL-1L on the
CFTR mRNA levels. As shown in Fig. 1, a biphasic
e¡ect was observed after treatment of T84 colonic
carcinoma cells with IL-1L for 4 h. Maximal IL-1L
stimulation was obtained at 0.25 ng/ml and inhibi-
tion at 1.00 ng/ml. The concentration of IL-1L to
obtain maximum response exhibited a variation in
the range of 0.25^0.50 ng/ml for separate experi-
ments (not shown). At concentrations of IL-1L of
1.00 ng/ml (Fig. 1) and higher (up to 5.0 ng/ml
were tested, results not shown), a strong inhibitory
e¡ect was observed, comparable to the inhibition
seen with TPA [21]. Although this is the ¢rst time
that a biphasic e¡ect for IL-1L is reported, similar
behavior has been observed for TNF-K [24], which
shares some intracellular pathways with IL-1L. Sim-
ilar biphasic e¡ects were seen by using Caco-2 and
LS180 cells (results not shown).
To determine whether the levels of the CFTR pro-
tein correlated with the modulation of its mRNA by
IL-1L, a Western blot analysis was performed. For
the analysis, we used the monoclonal antibody
M3A7, which recognizes the CFTR protein [23]. As
shown in Fig. 4, the CFTR protein was elevated in
the presence of IL 1L (0.5 ng/ml) and decreased in
the presence of IL 1L at 2.5 ng/ml. The protein levels
were also diminished in the presence of TPA (100 ng/
ml). These results show a good correlation with those
obtained by Northern blot analysis, indicating that
IL-1L a¡ects both the CFTR mRNA and protein.
Although IL-1L up-regulates the CFTR gene and
protein, this is done in a very narrow range (around
0.25^0.5 ng/ml). At higher concentrations (1 ng/ml
and over), a very strong inhibition of the message
Fig. 1. Northern blot analysis of CFTR expression in T84 cells
treated with IL-1L. T84 human carcinoma cells were treated
with varying concentrations of IL-1L for 4 h. Northern blot
analysis was then performed using total RNA (30 Wg) and a
3.3-kb CFTR cDNA probe. The image was quanti¢ed and nor-
malized for RNA loading using the rRNAs of the same mem-
brane, stained with methylene blue (indicated as 28S). In di¡er-
ent experiments, the maximum response varied between 0.25^
0.5 ng/ml. Quanti¢cation of CFTR mRNA expression is shown
in the bottom panel. Values are mean þ S.E.M.(n = 6) expressed
as percentage of control. Signi¢cant di¡erences compared to 0.1
ng/ml IL-1L : *P6 0.01.
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and protein was observed. Interestingly, the inhibi-
tory e¡ect of IL-1L on the CFTR protein was even
stronger than the e¡ect obtained with TPA at 100 ng/
ml. This is noteworthy, since the CFTR protein has
normally a long half-life time (longer than 24 h) [25].
Therefore, it seems that IL-1L, at high doses, not
only reduces mRNA levels for CFTR, but also re-
duces the protein half-life.
To determine whether the up-regulation of the
CFTR by IL-1L required de novo synthesis of pro-
teins, control and stimulated cells were incubated
with cycloheximide (CHX). In the presence of
CHX (35.5 WM), both basal and IL-1L (0.50 ng/ml)
stimulated cells showed a decrease in the CFTR
mRNA levels, suggesting that maintenance of basal
and stimulated steady-state levels of the CFTR
mRNA requires de novo protein synthesis (Fig.
2A). To study whether the e¡ects of IL-1L were
due to increased CFTR mRNA stability, cells were
incubated in the presence or absence of IL-1L (0.50
ng/ml for 4 h), and then were exposed to DRB (78
Fig. 2. Northern blot analysis of CFTR in T84 cells treated
with IL-1L and cycloheximide (CHX) and DRB. (A) T84 cells
were pre-incubated for 30 min in the presence or absence of
CHX (35.5 WM) and then incubated for 4 h with IL-1L (0.25
ng/ml). Then, Northern analysis was performed on total RNA
(30 mg). The rRNA on the same membrane (indicated as 28S)
was stained with methylene blue to control for sample loading.
Inhibition of both basal and IL-L stimulated cells was observed.
Quanti¢cation of CFTR mRNA expression is shown in the bot-
tom panel. Values are mean þ S.E.M.(n = 2) expressed as per-
centage of control. Signi¢cant di¡erences as compared to 0.25
ng/ml IL-1L : **P6 0.05. (B) T84 cells were incubated in the
presence (open squares) or in the absence (closed squares) of
IL-1L (0.5 ng/ml) for 4 h. Then, DRB (78 WM) was added to
block further transcription and the CFTR mRNA levels where
determined at di¡erent times (4^16 h) by using Northern blot
analysis on total RNA (30 Wg).
6
C
Fig. 3. E¡ects of PKC and PTK inhibitors on the up-regulation
of the CFTR by IL-1L. T84 cells were preincubated with PKC
inhibitors (H7 50 WM and GF109203X 1.0 WM) and PTK in-
hibitors (genistein 60 WM and herbymicin A 2 WM) for 30 min
and then incubated for 4 h in the presence or absence of IL-1L
at concentrations that elicit maximum stimulation (0.25^0.5 ng/
ml depending on the IL-1L batch). Northern blot analysis for
CFTR was then performed on total RNA (30 Wg). (A) IL-1L
0.25 ng/ml, H7, GF109203X. (B) IL-1L 0.5 ng/ml, genistein. (C)
IL-1L 0.5 ng/ml, herbymicin A. Immediately after transference,
rRNA (28S) on the same membrane was stained with methylene
blue, to control for sample loading. Quanti¢cation of CFTR
mRNA expression is shown in the bottom panel of each ¢gure.
Values are mean þ S.E.M. (n = 3) expressed as percentage of
control. Signi¢cant di¡erences compared to the maximum IL-1L
response: *P6 0.01; **P6 0.05
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WM) for 4^16 h. CFTR mRNA levels decreased sim-
ilarly in both cases (control and IL-1L-treated cells)
(Fig. 2B), with a slight increase in the slope of the
IL-1L-treated cells. These results suggest that the up-
regulation in the CFTR mRNA steady-state levels
induced by IL-1L (at low doses) does not re£ect an
increased stability of the CFTR transcripts. Interest-
ingly, IL-1L behaves di¡erently from TNF-K, that
produces down-modulation of CFTR mRNA due
to changes in message stability [13].
Di¡erent protein-kinase inhibitors were then used
to obtain preliminary evidence about possible mech-
anisms involved in the up-regulation of the CFTR
mRNA induced by IL-1L. First, we studied the ef-
fects of the PKC inhibitors H7 and GF109203X. As
shown in Fig. 3A, both PKC inhibitors were able to
inhibit IL-1L induction of CFTR mRNA, suggesting
that a PKC isoform might be involved in the mech-
anism of up-regulation of CFTR induced by IL-1L.
Similar results have been reported in osteoblast-like
cells, in which induction of IL-6 by IL-1 seems to be
mediated by PKC [26]. Both inhibitors also a¡ected
basal levels of CFTR expression, although a stronger
e¡ect was obtained with H7.
Then, we decided to test whether protein tyrosine
kinases (PTKs) also might be involved in the up-reg-
ulation induced by IL-1L. Cells were preincubated
for 30 min with genistein (60 WM) and herbymicin
A (2 WM) as selective PTK inhibitors. Under these
conditions, inhibition of the IL-1L-stimulated CFTR
expression was observed with both inhibitors (Fig.
3B,C). Inhibition of basal CFTR levels was observed
only in the presence of genistein. These results sug-
gest that a PTK-dependent pathway might be also
involved in the up-regulation of the CFTR mRNA
induced by IL-1L. Other researchers obtained similar
results with the bradykinin B1 receptor gene, which
is up-regulated by IL-1L [27] by a PTK. However,
the regulation of the bradykinin receptor by IL-1L
does not requires protein synthesis, it is achieved
through a PTK and not PKC, and showed both tran-
scriptional activation and post-transcriptional
mRNA stabilization. On the other hand, the synthe-
sis of IL-8 is stimulated in HT-29 cells (also a colon
cell line) by IL-1L in a way that is independent of
PKC, but depends on protein tyrosine-phosphoryla-
tion [28]. Therefore, in T84 cells, the response of the
CFTR gene to IL-1L appears to be di¡erent, since
the up-regulation of the CFTR by IL-1L requires
both a PKC and a PTK.
It is interesting that IL-1L is elevated in the spu-
tum from CF patients [10], possibly as a result of the
chronic infection with Pseudomonas aeruginosa.
Therefore, IL-1L cytokine might reach enough con-
centration in situ to produce a strong inhibition of
the CFTR gene and protein expression. In CF pa-
tients, such a strong inhibitory e¡ect could poten-
tially deteriorate even more the already a¡ected ac-
cessibility of the CFTR mutated protein to the
plasma membrane [29]. Therefore, it would be very
important to further elucidate the mechanisms in-
volved in the biphasic response obtained with IL-1L
on CFTR, which might facilitate the identi¢cation of
new targets for possible therapy.
In summary, we present here the ¢rst evidence for
a regulatory role of IL-1L on CFTR expression. Us-
ing speci¢c inhibitors, we have obtained preliminary
evidence suggesting that a PKC isoform and at least
one PTK might be involved in the up-regulation of
Fig. 4. Immunoblot analysis of CFTR expression in T84 cells
in response to IL-1L. T84 cells were incubated for 4 h in the
presence/absence of IL-1L or TPA. Solubilized T84 proteins
(100 Wg) were separated on a 7% SDS-polyacrylamide gel and
probed with the monoclonal antibody M3A7 that recognizes
the CFTR protein. The spots were detected by using chemilu-
minescence. Quanti¢cation of CFTR protein expression is
shown in the bottom panel. Values are mean þ S.E.M. (n = 4)
expressed as percentage of control. Signi¢cant di¡erences com-
pared to maximum response to IL-1L : *P6 0.01.
BBADIS 61905 20-1-00
E.G. Ca¡erata et al. / Biochimica et Biophysica Acta 1500 (2000) 241^248246
CFTR by IL-1L. The possible mechanisms involved
in the down-modulation of CFTR by IL-1L at doses
of 1.00 ng/ml and higher are unknown, although they
might be similar to those involved in the down-mod-
ulation induced by treatments with TNF-K and TPA.
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